Eli Lilly has reported strong second-quarter 2026 financial results, posting a 48% year-over-year increase in revenue to $23 billion as demand for its diabetes and obesity therapies, Mounjaro and Zepbound, continued to accelerate. The pharmaceutical company also raised its full-year revenue guidance, reflecting sustained growth across its product portfolio and continued investment in next-generation treatments and manufacturing expansion.

Eli Lilly delivered another quarter of robust financial growth, reporting second-quarter 2026 revenue of $22.97 billion, up 48% from the same period last year, driven largely by continued demand for its blockbuster diabetes and obesity medicines, Mounjaro and Zepbound.

The company also increased its full-year revenue forecast to between $85 billion and $87 billion, citing stronger-than-expected commercial performance, expanding global demand, and momentum across its broader pharmaceutical portfolio.

Net income for the quarter reached $7.1 billion, while reported earnings per share rose 26% year over year to $7.94. On a non-GAAP basis, earnings per share increased 33% to $8.38, despite higher research investments and acquisition-related charges tied to recent business development activities.

The strongest contributor remained Mounjaro, Lilly’s diabetes therapy based on tirzepatide, which generated $9.94 billion in quarterly sales, representing 91% growth compared with the second quarter of 2025. The company’s obesity treatment Zepbound contributed $4.93 billion, increasing 46% year over year as demand remained strong in the U.S. market.

International markets also emerged as a significant growth driver. Revenue outside the United States climbed 80%, fueled primarily by expanding adoption of Mounjaro following its inclusion in China’s National Reimbursement Drug List. While pricing pressures affected international revenue, higher prescription volumes more than offset lower realized prices.

Beyond commercial performance, Lilly continued investing aggressively in research, development, and manufacturing capacity. Research and development spending increased 14% to $3.8 billion, supporting late-stage clinical programs and pipeline expansion. Marketing and administrative expenses also rose as the company prepared for new product launches across multiple therapeutic areas.

During the quarter, Lilly recorded $2.8 billion in acquired in-process research and development charges related primarily to acquisitions involving Orna Therapeutics and Ajax Therapeutics. Additional restructuring and integration costs followed the completion of acquisitions involving Kelonia Therapeutics and Centessa Pharmaceuticals, reflecting the company’s strategy of strengthening its pipeline through targeted business development.

Pipeline progress remained another highlight of the quarter. Lilly reported positive clinical developments across obesity, oncology, diabetes, cardiovascular disease, immunology, and neuroscience.

Particular attention continues to focus on retatrutide, Lilly’s next-generation triple-hormone agonist for obesity treatment. The company announced successful Phase 3 clinical results demonstrating significant weight reduction and improvements in blood sugar control, further strengthening expectations that the therapy could become one of the industry’s most important future obesity medicines.

Lilly also reported encouraging results for Foundayo (orforglipron), its oral GLP-1 therapy, which delivered positive outcomes across multiple pivotal Type 2 diabetes studies while demonstrating meaningful weight-loss benefits. Unlike injectable GLP-1 therapies, Foundayo can be taken without food or water restrictions, potentially offering patients greater convenience if approved across additional markets.

The company’s oncology pipeline also advanced during the quarter, with Jaypirca receiving a positive recommendation from European regulators for chronic lymphocytic leukemia, while several additional cancer therapies achieved important clinical milestones.

Competition within the obesity market remains intense, with Novo Nordisk continuing to compete through products including Wegovy and Ozempic. However, Lilly has rapidly expanded its market position through strong commercial execution, manufacturing investments, and continued clinical development of next-generation metabolic therapies.

The company also announced an additional $4.5 billion investment across its Indiana manufacturing facilities while opening its first dedicated genetic medicine production site. These investments aim to expand manufacturing capacity as demand for GLP-1 therapies continues to outpace industry supply.

For investors, Lilly’s updated financial guidance signals confidence in continued commercial momentum despite pricing pressures and rising acquisition costs. The company now expects performance margins between 49% and 50.5%, up from previous guidance, reflecting improved operating efficiency and higher product volumes.

As Lilly celebrates its 150th year, the company continues positioning itself for long-term growth through a combination of blockbuster commercial products, pipeline innovation, strategic acquisitions, and expanded manufacturing infrastructure. With obesity, diabetes, oncology, and genetic medicines expected to remain major growth areas across the pharmaceutical industry, Lilly appears well positioned to capitalize on one of healthcare’s fastest-growing therapeutic markets.

Top Insights

  • Eli Lilly reported 48% revenue growth in Q2 2026, driven primarily by continued global demand for Mounjaro and Zepbound across diabetes and obesity markets.
  • The company raised its 2026 revenue guidance to $85-87 billion while improving expected operating margins despite significant acquisition-related investments.
  • Mounjaro generated nearly $10 billion in quarterly sales, reinforcing Lilly’s leadership in the rapidly expanding GLP-1 and obesity treatment market.
  • Lilly advanced multiple late-stage clinical programs, including retatrutide and oral GLP-1 therapy Foundayo, strengthening its long-term product pipeline.
  • Strategic acquisitions and expanded manufacturing investments highlight Lilly’s focus on scaling production and accelerating pharmaceutical innovation.

Have a story or business inquiry?Contact our FinTechEdition team today.

Source: Eli Lilly and Company